Guidance for future HTA applications to vaccines: The HPV lesson

Human Vaccines

Volumn 7, Issue 9, 2011, Pages 900-904

  La Torre, Giuseppe ^a,b   De Waure, Chiara ^a   Chiaradia, Giacomina ^c   Mannocci, Alice ^b   Capri, Stefano ^d   Bamfi, Francesco ^e   Ricciardi, Walter ^a  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Spallanzani Institute ^*  (Italy)

^d CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^e GSK   (Italy)

Author keywords

Assessment; HPV; HTA; Public health; Vaccine

Indexed keywords

WART VIRUS VACCINE;

DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG SCREENING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH SERVICE; HEALTH TECHNOLOGY ASSESSMENT; ITALY; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; VACCINATION;

BIOMEDICAL TECHNOLOGY; FORECASTING; HEALTH PLANNING GUIDELINES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TECHNOLOGY ASSESSMENT, BIOMEDICAL; VACCINATION;

EID: 80053605723     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.9.16084     Document Type: Review

References (23)

1. WHO. UNICEF, GIVS. Global Immunization Vision and Strategy 2006-2015. Available online from: http://www.who.int/vaccines-documents/DocsPDF05/GIVS- Final-EN.pdf [accessed on February 2011].
2. Peny JM, Gleizes O, Covilard JP. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Vaccine 2005; 23:4610-8; PMID:15979769; DOI:10.1016/j.vaccine.2005.04.044.
3. La Torre G, Chiaradia G, De Waure C, Mannocci A, Capri S, Bruno S, et al. Health Technology Assessment and vaccine: new needs and opportunities? Ital J Public Health 2007; 5:81-8.
4. La Torre G, De Waure C, Chiaradia G, Mannocci A, Specchia ML, Nicolotti N, et al. The future of best investing in vaccines: the Health Technology Assessment approach. Vaccine 2008; 26:1609-10; PMID:18289744; DOI:10.1016/j.vaccine.2008.01.009.
5. La Torre G, Chiaradia G, Mannocci A, De Waure C, Ricciardi W, Capri S, et al. Health Technology Assessment della vaccinazione anti-HPV [Health Technology Assessment of HPV vaccination]. Ital J Public Health 2007; 4:1-60.
6. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-15; PMID:15100338; DOI:10.1093/jnci/djh104.
7. Health Protection Agency. Press release. 2007 Available online from: http://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListDate/Page/ 1253205582282 [accessed on February 2011].
8. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-9; PMID:12915431; DOI:10.1001/jama.290.6.781.
9. National Board of Health. Danish Centre for Health Technology Assessment 2007. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a Health Technology Assessment. Copenhagen 2007; 9. Available online from: http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV-vaccination- smfatn-en.pdf [accessed on February 2011].
10. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37-48; PMID:12533280.
11. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915-23; PMID:15550200.
12. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; DOI:10.1016/S0140-6736(09)61248-4.
13. La Torre G, Chiaradia G, De Waure C, Nicolotti N, Monteduro A. Report HTA del vaccino quadrivalente anti-HPV Gardasil [Health Technology Assessment of tetravalent HPV vaccine]. Ital J Public Health 2009; 6:1-66.
14. Reparto Epidemiologia delle Malattie Infettive del CNESPS. ISS del Gruppo Sanità Coordinamento Interregionale della Prevenzione. Ricognizione delle decisioni regionali in merito alla vaccinazione anti-HPV e stato di avanzamento dei programmi vaccinali nelle regioni italiane a fine anno 2008 [Epidemiology and Infectious Diseases CNESPS ISS Department and Health Group on Interegional Coordination of Prevention. Recognition of regional decisions on HPV vaccination and state of the art of vaccination programmes in Italian Regions by the end of 2008]. Available online from: http://www.tumori.net/it/ brochures/documenti/campagna-Hpv08.pdf [accessed on February 2011].
15. WHO. Health Evidence Network. Available online from: http://www.euro.who. int/en/what-we-do/data-and-evidence/health-evidence-network-hen [accessed on April 2011].
16. WHO. European Observatory on Health Systems and Policies. Available online from: http://www.euro.who.int/en/home/projects/observatory [accessed on April 2011].
17. INAHTA. Available online from: http://www.inahta.org [accessed on April 2011].
18. EUnetHTA. Available online from: http://www.eunethta.net/[accessed on April 2011].
19. Russo P. La valutazione farmacoeconomica nel contesto regolatorio italiano. Analisi quali-quantitativa dei dossier di richiesta del prezzo e della rimborsabilità. [Pharmacoeconomic evaluations in the Italian regulatory context: a quali quantitative analysis of pricing and reimbursement dossiers]. PharmacoEconomics - Italian Research Articles 2008; 10:59-75.
20. De Vito C, Marzuillo C, Villari P. The public health evaluation of vaccines. Ital J Public Health 2009; 6:179-82.
21. Piana A, Sotgiu G, Castiglia P, Pischedda S, Dettori M, Cocuzza C, et al. Molecular methods for the detection of human papillomavirus infection: new insights into their role in diagnostics and epidemiological surveillance. Ital J Public Health 2009; 6:164-71.
22. Health Data OECD 2004; 1.
23. La Torre G. Assessment of HPV vaccines: From the burden of disease to the Health Technology Assessment approach. Hum Vaccin 2010; 6:915-7; PMID:20061790; DOI:10.4161/hv.6.11.12853.